Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765323 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
A Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT00765323: Clinical Trial Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00765323 is a Phase 3 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00765323, a Phase 3 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.
Interventions
- DRUG Sandostatin LAR Depot
- DRUG Octreotide Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765323
The ClinicalTrials.gov registry entry for NCT00765323 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sandostatin LAR Depot is the first listed.
NCT00765323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765323 about?
NCT00765323 is a clinical study titled "Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly". Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.
What is the current status of trial NCT00765323?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2008-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00765323?
The interventions under investigation include: Sandostatin LAR Depot (DRUG), Octreotide Implant (DRUG).
Who is sponsoring clinical trial NCT00765323?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.